FDA says Innovative Formulations, doing business as Insane Labz, sells Wake the Dead Smelling Salts, an unapproved ammonia stimulant drug, online.
What happened
FDA reviewed the company’s website on November 14, 2023, and its Amazon storefront on February 14, 2024, where WAKE THE DEAD SMELLING SALTS was for sale in the United States. The labeling said the product releases ammonia gas when hydrated, triggers a strong inhalation reflex, and affects breathing muscles, heart rate, blood pressure, and brain activity. FDA determined the product is intended as a stimulant drug, is an unapproved new drug, and is misbranded.
What FDA found
FDA calls the product a “new drug”—a drug that needs FDA approval or must be generally recognized as safe and effective—and says no approved application is in effect for it.
FD&C Act section 505(a), 21 U.S.C. 355(a)FDA calls the product misbranded—illegally labeled—because it is a nonprescription drug that does not meet the requirements for marketing without an approved application.
FD&C Act section 502(ee), 21 U.S.C. 352(ee)FDA says the product is a drug because its labeling claims it affects breathing, heart rate, blood pressure, and brain activity.
FD&C Act section 201(g)(1)(B)/(C), 21 U.S.C. 321(g)(1)(B)/(C)FDA says ammonia in a product labeled as a reflex stimulant is not generally recognized as safe and effective under a 2008 proposed rule.
FD&C Act section 505G(a)(4), 21 U.S.C. 355h(a)(4)Even as a general stimulant, the product does not meet FDA’s over-the-counter stimulant rule, Monograph M011, because it contains ammonium chloride and is labeled for intranasal use, while M011 allows caffeine by mouth as the only stimulant active ingredient.
FD&C Act section 505G; OTC Monograph M011FDA says sending the product into interstate commerce is prohibited because it is an unapproved and misbranded drug.
FD&C Act sections 301(a) and 301(d), 21 U.S.C. 331(a) and (d)
What FDA wants
Tell FDA in writing within 15 working days what the company has done to fix the violations and prevent recurrence, or explain the delay and give a completion schedule. If the company believes the product is legal, it must send its reasoning and supporting information.
Who should pay attention
- retailers and online marketplaces selling stimulant or smelling-salt products
- brands that market ammonia inhalants or over-the-counter stimulants
- quality teams reviewing over-the-counter drug labeling and claims
This is a summary. Read the original letter on fda.gov.